National Research Corporation (NRC): Fair Value Consensus

National Research (NRC) is based on a cloud-first approach, utilizing distributed servers to analyze the quality of medical care. The company's SaaS solutions ensure high scalability with minimal code development costs, while data collection is delegated to external partners under strict security controls. The market price trend on GURU.Markets, which currently stands at 27.08, confirms the efficiency of this operating model.

NRC National Research: Analyst Consensus Forecast in the range 07/04/2022 - 11/11/2026

National Research Corporation (NRC) - metric breakdowns and financial figures

- stock price and consensus target price:

Share Price nrchealth.com|NRC - Price Target Chart

- stock exchange capitalization data:

Market Value NRC Health Inc.|NRC - Enterprise Value

- book capitalization indicators:

Accounting Value per Share NRC Health|NRC - Book Capitalization|Market Capitalization to Book Value nrchealth.com|NRC - Cumulative Company Assets

- debt obligations and liquidity statistics:

- business earnings and investment ratios data:

NRC - Company Net Income|Net Profit Forecast National Research|NRC - P/E Multiple|Forward P/E Multiple National Research|NRC - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio NRC Health Inc.|NRC - Operating profit EBITDA|Net earnings per share for the last four quarters NRC Health|NRC - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months nrchealth.com|NRC - Earnings per share growth in current year|Projected earnings per share growth rate for next year National Research

Fundamental company analysis:NRC (National Research Corp.)

This price action reflects a comprehensive revaluation of the asset's fundamental value based on expected cash flows, capturing the speed at which expert expectations are adjusted as market conditions shift. An analysis of the market's price target for National Research (NRC) allows for an assessment of the business's resilience against fierce competition in medtech, where proprietary databases determine the company's long-term attractiveness to analysts.

Competing companies